<DOC>
	<DOCNO>NCT01473524</DOCNO>
	<brief_summary>The investigational drug , Obeticholic Acid ( OCA ) modify bile acid FXR agonist . FXR key regulator bile acid synthesis transport . Bile acid use body help digestion . It hypothesize regular treatment OCA improve liver function person Primary Biliary Cirrhosis ( PBC ) .</brief_summary>
	<brief_title>Phase 3 Study Obeticholic Acid Patients With Primary Biliary Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Liver Cirrhosis , Biliary</mesh_term>
	<mesh_term>Chenodeoxycholic Acid</mesh_term>
	<criteria>1 . Definite probable PBC diagnosis ( consistent American Association Study Liver Disease [ AASLD ] European Association Study Liver [ EASL ] Practice Guidelines ; [ Lindor 2009 ; EASL 2009 ] ) , demonstrate presence ≥ 2 follow 3 diagnostic factor : History elevate Alkaline Phosphatase level least 6 month Positive antimitochondrial antibody ( AMA ) titer AMA negative low titer ( &lt; 1:80 ) PBC specific antibody ( antiGP210 and/or antiSP100 and/or antibody major M2 component ( PDCE2 , 2oxoglutaric acid dehydrogenase complex ) Liver biopsy consistent PBC 2 . At least 1 follow qualify biochemistry value : ALP ≥ 1.67x upper limit normal ( ULN ) Total bilirubin &gt; ULN &lt; 2x ULN 3 . Age ≥ 18 year 4 . Taking ursodeoxycholic acid ( UDCA ) least 12 month ( stable dose ≥ 3 month ) prior Day 0 , unable tolerate UDCA ( UDCA ≥ 3 month ) prior Day 0 . 5 . Contraception : Female patient must postmenopausal , surgically sterile , premenopausal , prepare use ≥ 1 effective ( ≤ 1 % failure rate ) method contraception trial 30 day end treatment ( EOT ) visit . Effective method contraception consider : Hormonal ( e.g. , contraceptive pill , patch , intramuscular implant injection ) ; Double barrier method , i.e. , ( ) condom ( male female ) ( b ) diaphragm , spermicide ; Intrauterine device ( IUD ) ; Vasectomy ( partner ) 6 . Must provide write informed consent agree comply trial protocol . 1 . History presence concomitant liver diseases include : Hepatitis C virus ( HCV ) infection ; patient active hepatitis B ( HBV ) infection exclude , however , patient seroconverted ( Hbs Ag Hbe Ag negative ) may include consultation medical monitor . Primary sclerosing cholangitis ( PSC ) Alcoholic liver disease Definite autoimmune liver disease overlap hepatitis Nonalcoholic steatohepatitis ( NASH ) Gilbert 's Syndrome ( due interpretability bilirubin level ) 2 . Presence clinical complication PBC clinically significant hepatic decompensation , include : History liver transplantation , current placement liver transplant list current Model End Stage Liver Disease ( MELD ) score ≥ 15 Portal hypertension complication , include : know gastric large esophageal varix , poorly control diuretic resistant ascites , history variceal bleeds relate therapeutic prophylactic intervention ( e.g. , beta blocker , insertion variceal band transjugular intrahepatic portosystemic shunt [ TIPS ] ) , hepatic encephalopathy Cirrhosis complication , include history presence : spontaneous bacterial peritonitis , hepatocellular carcinoma , bilirubin &gt; 2x ULN Hepatorenal syndrome ( type I II ) Screening serum creatinine &gt; 2 mg/dL ( 178 μmol/L ) 3 . Patients severe pruritus require systemic treatment pruritus ( e.g. , bile acid sequestrants [ BAS ] rifampicin ) within 2 month Day 0 exclude 4 . Administration follow medication prohibit specify : Prohibited 6 month prior Day 0 throughout trial ( i.e. , last dose last dose and/or EOT ) : azathioprine , colchicine , cyclosporine , methotrexate , mycophenolate mofetil , pentoxifylline ; fenofibrate fibrates ; budesonide systemic corticosteroid ; potentially hepatotoxic drug ( include αmethyldopa , sodium valproic acid , isoniazide , nitrofurantoin ) Prohibited 12 month prior Day 0 throughout trial ( i.e. , last dose last dose and/or EOT ) : antibody immunotherapy direct interleukin cytokine chemokines 5 . Patients previously participate clinical trial OCA allow participate 6 . History presence clinically concern cardiac arrhythmia likely affect survival trial , prolongation Screening ( pretreatment ) QT QTc interval &gt; 500 millisecond ( msec ) 7 . If female : know pregnancy , positive urine pregnancy test ( confirm positive serum pregnancy test ) , lactate 8 . Known history human immunodeficiency virus ( HIV ) infection 9 . Presence disease condition interfere absorption , distribution , metabolism , excretion drug include bile salt metabolism intestine . Patients inflammatory bowel disease undergone gastric bypass procedure exclude ( gastric lap band acceptable ) . 10 . Medical condition may cause nonhepatic increase ALP ( e.g. , Paget 's disease ) may diminish life expectancy &lt; 2 year , include know cancer ( except carcinoma situ stable , relatively benign condition chronic lymphatic leukemia ) 11 . Other clinically significant medical condition well control medication need anticipated change trial 12 . Anticipated change current concomitant medication course trial 13 . History alcohol abuse , define consumption 210 mL alcohol per week ( i.e. , equivalent 14 4ounce ( 125 mL ) glass wine 14 12 ounce cans/bottles beer ) , substance abuse within 1 year prior Day 0 14 . Participation another investigational drug , biologic , medical device trial within 30 day prior Screening 15 . History noncompliance medical regimen , patient consider potentially unreliable 16 . Blood plasma donation within 30 day prior Day 0 17 . Mental instability incompetence , validity inform consent compliance trial uncertain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Primary Biliary Cholangitis</keyword>
	<keyword>Primary Biliary Cirrhosis</keyword>
	<keyword>PBC</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>Liver</keyword>
</DOC>